Adam Kittai, MD, discusses how value and waste in treatment are imperative to consider in value-based care for blood-based cancers.
Maximizing the value of treatment and ensuring that money is spent wisely are 2 important aspects to consider in value-based care for blood-based cancer, explains Adam Kittai, MD, assistant professor in the division of hematology at The Ohio State University-James Cancer Hospital and Solove Research Institute.
Transcript
Why is value-based care important when treating patients with a blood-based cancer such as leukemia?
I think there are 2 main reasons why value-based care is important here. One, for anyone that has a malignancy, it's important that the patient can derive as much value as they can from the treatment they receive, and with the time that they have. Life is uncertain in any circumstance, and when you are dealing with a serious life event, like cancer, deriving value from what we have is made a very high priority.
Your other reason is cost and waste. As these new drugs are being developed for hematologic malignancies, the cost of cancer is rising exponentially. So, as costs are rising, it puts a significant stress on our health care system overall. It also creates disparities in access to care.
Higher costs also lead to higher wastes, and it's important that we derive as much value as we can from every dollar spent, given money is not an unlimited commodity, allowing us to not only take great care of the patient in front of us, but all but all of society as a whole.
When I think about why value-based care is important when treating patients with a blood-based cancer, I think the 2 main things that I can think of are that we really want to derive as much value of the time that we have and the treatment that we give, and also really think about the cost of the care that we give.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More